Extended Data Fig. 3: Patient survival outcomes.
From: Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
a, Best percent change from baseline over time per RECIST v1.1 criteria for patients in the total intention-to-treat cohort. b, Kaplan–Meier estimates of progression-free survival assessed according to RECIST v1.1 for patients in the total intention-to-treat cohort. c, Kaplan–Meier estimates of overall survival assessed according to RECIST v1.1 for patients in the total intention-to-treat cohort. d, Kaplan–Meier estimates of time on treatment assessed according to RECIST v1.1 for patients in the total intention-to-treat cohort. e, Kaplan-Meier estimates of progression-free survival assessed according to RECIST v1.1 for patients without prior receipt of a BRAF inhibitor and/or immunotherapy, and with microsatellite stability in the intention-to-treat cohort. f, difference in PFS by sidedness for patients in the total intention-to-treat cohort (Cox regression test). g, ORR, PFS, and OS information of patients with prior BRAFi or ICB.
